Axonics ModulationTechnologies Inc

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axonics reports record Q4 revenue, eyes global expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q4 2022, with record revenue, solid margins, and profitability, while reiterating revenue guidance for 2023.
The company's focus on innovation, market leadership in sacral neuromodulation, and global expansion plans position it well for future growth despite challenges in international markets and legal uncertainties.
Opportunities in the U.S. and Asian markets, coupled with strategic initiatives like direct-to-consumer campaigns and product enhancements, offer avenues for sustained revenue growth and market dominance.

Axonics reports robust Q1 earnings, eyes market expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q1 2023, driven by revenue growth, operational efficiency, and strategic guidance updates for FY 2023.
The company's strengths lie in its robust commercial team, successful marketing campaigns, focus on innovation, and leadership's commitment to disciplined growth strategies.
While facing challenges such as legal uncertainties, coverage limitations, and margin management, Axonics has opportunities for market expansion, acquisitions, and technology advancements.
Overall, Axonics' performance, strengths, challenges, and opportunities position the company for continued growth and market leadership in the neuromodulation industry.

Axonics Modulation Technologies Reports Record Q2 Revenue Growth

Axonics Modulation Technologies delivered a strong performance in Q2, driven by revenue growth and operational efficiency.
The company's strengths lie in international expansion, robust commercial efforts, and continuous product innovation.
Challenges include legal uncertainties, market dynamics, and strategic positioning in a competitive landscape.
Opportunities for growth include market expansion, rising adoption trends, and enhancing customer experience.

Axonics reports robust Q3 earnings, eyes growth through innovation

Axonics delivered strong financial performance, driven by SNM and Bulkamid revenue growth and improved margins.
The company's focus on innovation, customer feedback, and market leadership positions it well for future growth.
Challenges include maintaining growth momentum, high rep productivity, and balancing marketing strategies.
Opportunities lie in expanding product offerings, market share, and leveraging direct-to-consumer campaigns for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced European CE Mark approval of its second generation Axonics r-SNM® implantable neurostimulator (INS) and wireless patient remote control with SmartMRI™ technology. Axonics previously received U.S. Food & Drug Administration approval for this INS and remote control during 202

Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering price of $50.00 per share, which includes the exercise in full by the underwriters of the underwriters' option to purchase 525,000 additional shares at the public offering

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Stock

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common stock at a public offering price of $50.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and

Axonics® Announces Upsize and Pricing of Public Offering of Common Stock

Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 31, 2021. “This quarter's revenue result reflects growing demand for our long-lived r-SNM® system and Bulkamid® despite the resurgence of COVID cases in the U.S. in early 2021 and ongoing lockdowns in Europe,” said Raymond W. C

Axonics® Reports First Quarter 2021 Financial Results

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021. Axonics is scheduled to present at 12:30 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website. A

Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217

Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021

Becton, Dickinson and Co.

DexCom

Medtronic

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can help move the shares higher.

4 Medical Technology Leaders Have Upcoming Catalysts That Could Be Huge

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021. Axonics is scheduled to present at 10:55 a.m. Eastern Time. Interested parties may access the live and archived webcast of the presentation by visiting the Axonics inv

Axonics® to Participate in the Barclays Global Healthcare Conference

LISLE, Ill., March 2, 2021 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors. Mr....

Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies (MST), a leading manufacturer of medical microelectronics. MST currently manufactures printed circuit board assemblies for the Axonics r-SNM System in Lake Oswego, Oregon. This s

Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device

Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call Transcript

Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. The transaction includes a total consideration of $200 million in cash and stock, along with a potential future milestone of $35 million.

Axonics Acquires Urethral Bulking Agent For $200M

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020. Raymond W. Cohen, Axonics CEO, said, “In the first year of Axonics' commercial launch in the United States, we exceeded our ambitious goals despite

Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held Contura Ltd. and its flagship product, Bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (SUI). Axonics acquired London-based Contura Ltd. f

Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®

On Thursday, February 25, Axonics Modulation Tech (NASDAQ:AXNX) will release its latest earnings report. Benzinga's outlook for Axonics Modulation Tech is included in the following report.

Axonics Modulation Tech Earnings Preview

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parti

Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced it is participating as a platinum sponsor of the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2021 Winter Meeting, which is being held virtually from February 25-27. Axonics is

Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration (FDA) for its third-generation implantable neurostimulator (INS). This marks the sixth FDA approval Axonics has received for a significant product innov

Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021. Axonics' management team is scheduled to present at 11:20 a.m. Eastern Time. Interested parties may access the live and archived webcast of

Axonics® to Participate in the SVB Leerink Global Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020. Preliminary unaudited net revenue is expected to be in the range of $34.7 to $34.9 million in the fourth quarter 2020, as c

Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: G

Axonics® Announces Appointment of David M. Demski to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of fecal incontinence study results for patients treated with the Axonics r-SNM System. The study results were published in the peer-reviewed journal Neuromodulation, the official journal of the Interna

Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript

News for Axonics ModulationTechnologies Inc Stock (AXNX)